Body composition as a predictor of chemotherapy-related toxicity in ovarian cancer patients: A systematic review.
body composition
chemotherapy
ovarian cancer
sarcopenia
toxicity
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
29
09
2022
accepted:
21
10
2022
entrez:
21
11
2022
pubmed:
22
11
2022
medline:
22
11
2022
Statut:
epublish
Résumé
The main objective of this systematic review was to examine the literature evaluating association of image-based body composition with chemotherapy-related toxicity in ovarian cancer patients. A secondary objective was to evaluate the different definitions of sarcopenia across studies. This systematic review was conducted according to the PRISMA-DTA statement and the protocol was registered on Prospero. A comprehensive literature search of 3 electronic databases was performed by two authors. For each eligible article, information was collected concerning the clinical setting; basic study data; population characteristics; technical aspects; body composition features; chemotherapy drugs administered; association of body composition values and toxicities. The overall quality of the included studies was critically evaluated. After the initial retrieval of 812 articles, the systematic review included 6 articles (5/6 studies were retrospective; one was prospective). The number of patients ranged between 69 and 239; mean/median age ranged between 55 and 65 years; the percentage of sarcopenic patients ranged between 25% and 54%. The cut-off values to define sarcopenia and the vertebral levels for evaluation of body composition were different. Five studies included chemotherapy based on carboplatin and paclitaxel, 1 included chemotherapy based on pegylated liposomal doxorubicin. Among the studies including carboplatin and paclitaxel, 3/5 demonstrated an association with toxicity, whereas 2/5 did not. Altogether, 4/6 papers demonstrated an association between the body composition values and the development of chemotherapy-related toxicities. There is a wide variability of results about the association of body composition and chemotherapy-related toxicity in ovarian cancer patients. Therefore further studies, possibly including a comprehensive assessment of body compartments and where the definition of body composition cut-offs is constant, are warranted to better understand this association. https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022337753, identifier (CRD42022337753).
Identifiants
pubmed: 36408182
doi: 10.3389/fonc.2022.1057631
pmc: PMC9667042
doi:
Types de publication
Systematic Review
Langues
eng
Pagination
1057631Informations de copyright
Copyright © 2022 Rizzo, Raia, Del Grande, Gasparri, Colombo, Manganaro, Papadia and Del Grande.
Déclaration de conflit d'intérêts
The reviewer FT declared a shared affiliation with the author LM to the handling editor at the time of the review. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Ann Oncol. 2019 May 1;30(5):672-705
pubmed: 31046081
Am J Clin Oncol. 2017 Feb;40(1):47-52
pubmed: 24685884
Radiographics. 2021 Mar-Apr;41(2):524-542
pubmed: 33646902
Clin Cancer Res. 2009 Apr 15;15(8):2920-6
pubmed: 19351764
Lancet Oncol. 2015 Aug;16(8):928-36
pubmed: 26115797
Ann Oncol. 2010 Aug;21(8):1594-1598
pubmed: 20089558
JAMA Surg. 2018 Sep 1;153(9):809-815
pubmed: 29801062
Cancer Treat Rev. 2019 Nov;80:101909
pubmed: 31629204
Appl Physiol Nutr Metab. 2014 Jun;39(6):693-8
pubmed: 24869973
Int J Clin Oncol. 2019 Apr;24(4):437-444
pubmed: 30465138
Radiol Med. 2007 Aug;112(5):681-90
pubmed: 17657420
J Clin Oncol. 2022 Sep 9;:JCO2201549
pubmed: 36082969
Lancet Oncol. 2008 Jul;9(7):629-35
pubmed: 18539529
Clin Cancer Res. 2009 Nov 15;15(22):6973-9
pubmed: 19887488
J Clin Oncol. 2019 Sep 10;37(26):2317-2328
pubmed: 31216226
Breast J. 2018 May;24(3):278-284
pubmed: 29139618
Front Oncol. 2022 Sep 29;12:974116
pubmed: 36249069
Indian J Med Res. 2018 Nov;148(5):648-658
pubmed: 30666990
J Surg Oncol. 2018 Apr;117(5):1020-1028
pubmed: 29409111
NCHS Data Brief. 2020 Feb;(360):1-8
pubmed: 32487284
Am J Clin Nutr. 2010 Apr;91(4):1133S-1137S
pubmed: 20164322
Clin Transl Sci. 2021 Mar;14(2):720-728
pubmed: 33326171
Acta Oncol. 2021 Dec;60(12):1611-1620
pubmed: 34634224
Radiol Med. 2011 Jun;116(4):644-56
pubmed: 21424562
Cancer Chemother Pharmacol. 2017 Sep;80(3):555-561
pubmed: 28726081
JAMA. 2018 Jan 23;319(4):388-396
pubmed: 29362800
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
Front Oncol. 2022 Mar 15;12:826058
pubmed: 35372021
Ann Intern Med. 2011 Oct 18;155(8):529-36
pubmed: 22007046
Gynecol Oncol. 2020 Mar;156(3):695-700
pubmed: 31928805
Front Oncol. 2021 Nov 16;11:718815
pubmed: 34868915
Urol Oncol. 2020 Sep;38(9):713-718
pubmed: 32312642
N Engl J Med. 2019 Dec 19;381(25):2416-2428
pubmed: 31851799
J Clin Oncol. 2013 Apr 20;31(12):1539-47
pubmed: 23530101
Quant Imaging Med Surg. 2022 Feb;12(2):1450-1466
pubmed: 35111638
Lung Cancer. 2015 Oct;90(1):85-91
pubmed: 26198373
Quant Imaging Med Surg. 2020 Aug;10(8):1636-1649
pubmed: 32742957
Plast Reconstr Surg. 2014 Jul;134(1):13e-20e
pubmed: 25028829
Clin Pharmacokinet. 1994 Apr;26(4):292-307
pubmed: 8013162
N Engl J Med. 2019 Dec 19;381(25):2391-2402
pubmed: 31562799
Clin Cancer Res. 2017 Jul 15;23(14):3537-3543
pubmed: 28143874
Cancer. 2000 Feb 15;88(4):796-803
pubmed: 10679649